Novartis halts VHB937 ALS trial; Kisqali approved in Egypt
Novartis halted its mid-2011-stage VHB937 ALS trial after Phase 2 ASTRALS missed primary and secondary endpoints, while continuing to explore VHB937 for Alzheimer’s. Kisqali received approval in Egypt as adjuvant therapy for high-risk HR+/HER2- early breast cancer.